Danon disease pivotal readout is the make-or-break event for a newly approved gene therapy company with runway through Q2 2028

Bull

The three-patient safety cohort shows no TMA, capillary leak, or significant adverse events under the modified regimen, providing a credible safety narrative for FDA to accept the pivotal protocol. If FDA alignment is achieved in H2 2026 and additional patients are cleared for dosing, Rocket could accelerate enrollment toward a confirmatory dataset that supports an accelerated approval filing, leveraging the $322.6M cash runway through Q2 2028 to fund the program. A clean pivotal design confirmation would meaningfully re-rate the stock by removing execution uncertainty around the program's regulatory path.

Bear

FDA may require a longer observation period in the initial cohort or demand additional preclinical or manufacturing data before clearing the full pivotal enrollment, delaying the timeline materially beyond H2 2026. Even with safety cleared, the agency could require a larger or more complex endpoint structure that extends the trial duration and increases capital requirements beyond the current runway. Any recurrence of TMA or other serious adverse events in subsequently dosed patients would likely trigger another clinical hold and severely impair the program's viability.